Company news
Onkure Therapeutics, Inc. (NASDAQ:OKUR) news
Onkure Therapeutics, Inc. news releases on 6ix. Latest, Aug 31, 2026: OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
Press releases & updates
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
August 31, 2026
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 4, 2026
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
July 1, 2026
OnKure Therapeutics Reports First Quarter 2026 Financial Results
May 5, 2026
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
March 26, 2026
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 12, 2026
OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
November 6, 2025
OnKure Therapeutics to Participate in Upcoming Investor Conferences
November 4, 2025
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
August 12, 2025
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
May 6, 2025
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 10, 2025
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
March 4, 2025
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic Data from its First-In-Human PIKture-01 Trial of OKI-219
December 11, 2024
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
December 9, 2024
OnKure Announces New Date for Upcoming Investor Call
November 25, 2024
OnKure Therapeutics : INDEX TO UNAUDITED CONDENSED FINANCIAL STATEMENTS Form 8 K
November 7, 2024
OnKure to Present at the Stifel 2024 Healthcare Conference
November 5, 2024
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
October 31, 2024
ONKE THERPAR : Report of Independent Registered Public Accounting Firm Form 8 K
October 8, 2024
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
October 3, 2024
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
October 1, 2024
Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors
August 1, 2022
Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001
October 13, 2021
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
September 8, 2021
Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 10, 2021
Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
July 27, 2021
Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction
July 8, 2021
Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
June 28, 2021
Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 18, 2021